secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001023024-26-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma reports record Q4 revenue $247M, EPS $1.18; reaffirms 2026 guidance
------------------------------------------------------------------------------

- Q4 total net revenue $247.1M (+29.6% YoY); Rare Disease segment $131.3M (+50.8%), Cortrophin Gel $111.4M (+87.6%).
- Q4 GAAP diluted EPS $1.18; adjusted diluted EPS $2.33. Full year revenue $883.4M (+43.8%).
- Generics Q4 revenue $100.8M (+28.2%) driven by partnered launch and new products.
- Reaffirms FY2026 guidance: total revenue $1.055-1.115B; Cortrophin Gel $540-575M; adjusted EBITDA $275-290M.
- Cash and equivalents $285.6M; operating cash flow $185.2M in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302426000013/0001023024-26-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302426000013/ani-20260227.htm
  HTML page:      https://secwatch.observer/filing/0001023024-26-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer